{"id":604175,"date":"2022-06-15T20:32:01","date_gmt":"2022-06-15T20:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=604175"},"modified":"2022-06-15T20:32:01","modified_gmt":"2022-06-15T20:32:01","slug":"systemic-sclerosis-pipeline-2022-insights-into-the-clinical-trials-emerging-drugs-therapeutic-outlook-and-growth-prospects-key-players-gsk-forbius-fibrocell-novartis-genentech-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/systemic-sclerosis-pipeline-2022-insights-into-the-clinical-trials-emerging-drugs-therapeutic-outlook-and-growth-prospects-key-players-gsk-forbius-fibrocell-novartis-genentech-and-others_604175.html","title":{"rendered":"Systemic Sclerosis Pipeline, 2022: Insights Into the Clinical Trials, Emerging Drugs, Therapeutic Outlook, and Growth Prospects | Key Players &#8211; GSK, Forbius, Fibrocell, Novartis, Genentech, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Systemic Sclerosis Pipeline, 2022: Insights Into the Clinical Trials, Emerging Drugs, Therapeutic Outlook, and Growth Prospects | Key Players - GSK, Forbius, Fibrocell, Novartis, Genentech, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Systemic Sclerosis Pipeline, 2022: Insights Into the Clinical Trials, Emerging Drugs, Therapeutic Outlook, and Growth Prospects | Key Players - GSK, Forbius, Fibrocell, Novartis, Genentech, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cSystemic Sclerosis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Sclerosis Market.<\/div>\n<p style=\"text-align: justify;\">The <strong>Systemic Sclerosis Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Systemic Sclerosis Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/c1f17369b7b9e4988b295ded32c772b3.jpg\" alt=\"Systemic Sclerosis Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Systemic Sclerosis Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Systemic Sclerosis<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li>\n<p>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>Systemic Sclerosis Treatment<\/strong>.<\/p>\n<\/li>\n<li>\n<p><strong>Systemic Sclerosis key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p><strong>Systemic Sclerosis Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Systemic Sclerosis market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &#8211; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/systemic-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/systemic-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Systemic Sclerosis Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">There are a number of treatments that can be effective in Systemic Sclerosis; however, they have many limitations. Most of the therapies have some adverse effects, and there is no single accepted medical treatment for aggressive fibromatosis. Thus, there is a high urgent demand for novel therapies that can overcome the limitations of existing therapies.<\/p>\n<p style=\"text-align: justify;\">To fulfill the unmet need, at present some of the key players at the global level are diligently involved in the development of therapies for the <strong>treatment of Systemic Sclerosis (SSc)<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Systemic Sclerosis Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Forbius&nbsp;<\/p>\n<\/li>\n<li>\n<p>Novartis<\/p>\n<\/li>\n<li>\n<p>Genentech<\/p>\n<\/li>\n<li>\n<p>Galapagos NV<\/p>\n<\/li>\n<li>\n<p>GNI Group<\/p>\n<\/li>\n<li>\n<p>CSL Behring<\/p>\n<\/li>\n<li>\n<p>Seattle Genetics<\/p>\n<\/li>\n<li>\n<p>Kyowa Hakko Kirin<\/p>\n<\/li>\n<li>\n<p>GlaxoSmithKline<\/p>\n<\/li>\n<li>\n<p>Corbus Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Kaken Pharmaceutical<\/p>\n<\/li>\n<li>\n<p>Fibrocell, Kadmon Corporation<\/p>\n<\/li>\n<li>\n<p>Cumberland Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others<\/p>\n<p style=\"text-align: justify;\"><strong>Systemic Sclerosis Therapies Covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Lenabasum<\/p>\n<\/li>\n<li>\n<p>Pirfenidone<\/p>\n<\/li>\n<li>\n<p>GLPG1690<\/p>\n<\/li>\n<li>\n<p>Brodalumab<\/p>\n<\/li>\n<li>\n<p>GSK2330811<\/p>\n<\/li>\n<li>\n<p>KD025<\/p>\n<\/li>\n<li>\n<p>Vasculan<\/p>\n<\/li>\n<li>\n<p>FCX-013<\/p>\n<\/li>\n<li>\n<p>AVID200<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many more.<\/p>\n<p style=\"text-align: justify;\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; &nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/systemic-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/systemic-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Systemic Sclerosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Systemic Sclerosis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Systemic Sclerosis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Systemic Sclerosis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Systemic Sclerosis Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Systemic Sclerosis Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Systemic Sclerosis Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Systemic Sclerosis Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Systemic Sclerosis Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Systemic Sclerosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Systemic Sclerosis Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Systemic Sclerosis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><em><strong>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/systemic-sclerosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/systemic-sclerosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/preeclampsia-market\">Preeclampsia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&ldquo;Preeclampsia Market&rdquo; report delivers an in-depth understanding of Preeclampsia, historical and forecasted epidemiology as well as the Preeclampsia market trends, emerging therapies, and key companies operating in the domain.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=systemic-sclerosis-pipeline-2022-insights-into-the-clinical-trials-emerging-drugs-therapeutic-outlook-and-growth-prospects-key-players-gsk-forbius-fibrocell-novartis-genentech-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=systemic-sclerosis-pipeline-2022-insights-into-the-clinical-trials-emerging-drugs-therapeutic-outlook-and-growth-prospects-key-players-gsk-forbius-fibrocell-novartis-genentech-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cSystemic Sclerosis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Sclerosis Market. The Systemic Sclerosis Pipeline report embraces in-depth commercial and clinical assessment &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/systemic-sclerosis-pipeline-2022-insights-into-the-clinical-trials-emerging-drugs-therapeutic-outlook-and-growth-prospects-key-players-gsk-forbius-fibrocell-novartis-genentech-and-others_604175.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[426,405,417,406,404],"tags":[],"class_list":["post-604175","post","type-post","status-publish","format-standard","hentry","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=604175"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604175\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=604175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=604175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=604175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}